Clinical development of therapeutic recombinant proteins

BioTechniques

Volumn 35, Issue 1, 2003, Pages 176-185

  Reichert, Janice M ^a   Paquette, Cherie ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PHASE TRANSITIONS; PROBABILITY; PROTEINS;

CLINICAL PHASES;

BIOTECHNOLOGY;

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BLOOD SUBSTITUTE; HEMOSTATIC AGENT; IMMUNOLOGIC AGENT; RECOMBINANT ENZYME; RECOMBINANT HORMONE; RECOMBINANT PROTEIN; WOUND HEALING PROMOTING AGENT;

ARTICLE; CLINICAL TRIAL; DRUG APPROVAL; DRUG CLASSIFICATION; DRUG DEVELOPMENT; FOOD AND DRUG ADMINISTRATION; PROBABILITY; UNITED STATES;

EID: 0038678770     PISSN: 07366205     EISSN: None     Source Type: Journal    
DOI: 10.2144/03351dd01     Document Type: Article

References (11)

1. Spilker, B. 1991. Establishing clinical trial objectives, p. 10-14. In Guide to Clinical Trials. Raven Press, New York.
2. Reichert, J.M. 2001. Clinical development of therapeutic medicines: a biopharmaceutical versus pharmaceutical product comparison. Drug Inf. J. 35:337-346.
3. Reichert, J.M. and C. Paquette. 2003. Therapeutic recombinant proteins: trends in U.S. approvals 1982 to 2002. Curr. Opin. Mol. Ther. 5:139-147.
4. Scott, H.S., S. Bunge, A. Gal, L.A. Clarke, C.P. Morris, and J.J. Hopwood. 1995. Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications. Hum. Mutat. 6:288-302.
5. Kakkis, E.D., J. Muenzer, G.E. Tiller, L. Waber, J. Belmont, M. Passage, B. Izykowski, J. Phillips, et al. 2001. Enzyme-replacement therapy in mucopolysaccharidosis I. N. Engl. J. Med. 344:182-188.
6. Hermansen, K., S. Madsbad, H. Perrild, A. Kristensen, and M. Axelsen. 2001. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 24:296-301.
7. Schiffmann, R., J.B. Kopp, H.A. Austin, III, S. Sabnis, D.F. Moore, T. Weibel, J.E. Balow, and R.O. Brady. 2001. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 285:2743-2749.
8. Eng, C.M., N. Guffon, W.R. Wilcox, D.P. Germain, P. Lee, S. Waldek, L. Caplan, G.E. Linthorst, et al. 2001. Safety and efficacy of recombinant human (α)-galactosidase A replacement therapy in Fabry's disease. N. Engl. J. Med. 345:9-16.
9. Milne, C.-P. 2002. Orphan products - pain relief for clinical development headaches. Nat. Biotechnol. 20:780-784.
10. Reichert, J.M. 2001. Monoclonal antibodies in the clinic. Nat. Biotechnol. 19:819-822.
11. DiMasi, J.A. 2001. Risks in new drug development: approval success rates for investigational drugs. Clin. Pharmacol. Ther. 69:297-307.